
Investigational Combination Of First-In-Class Bispecific Antibodies TALVEY®▼ (Talquetamab) And TECVAYLI®▼ (Teclistamab) ...
(MENAFN- GlobeNewsWire - Nasdaq) Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel, off-the-shelf approach in patients …